CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

NCT04758767 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CASI pharmaceuticals, Inc.